Mutations in KRAS related to colorectal cancer result in gain-of-function with a decrease in GTPase activity of RAS and hence an increase in GTP-bound RAS and consequent persistent activation of the signaling pathways responsible for cell proliferation and carcinogenic cellular transformation. This evidence concerns the gene KRAS and colorectal cancer.